Text Size
46 studies found for:    NR3C2

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Enrolling by invitation Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology
Condition: Kidney Failure, Chronic
Intervention: Drug: spironolactone
2 Recruiting Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Conditions: Obesity;   Insulin Resistance
Interventions: Drug: Spironolactone;   Drug: Placebo
3 Completed Hypoglycemia and the Mineralocorticoid Receptor
Condition: Hypoglycemia
Intervention: Drug: Eplerenone
4 Completed Mineralocorticoid Receptor in the Treatment of Severe Depression
Condition: Major Depression
Interventions: Drug: Spironolactone;   Drug: fludrocortisone;   Drug: escitalopram
5 Active, not recruiting Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
Conditions: Type 2 Diabetes Mellitus;   Vascular Disease
Interventions: Drug: Spironolactone;   Drug: hydrochlorothiazide + potassium;   Other: placebo
6 Completed Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study
Condition: Heart Failure
Intervention: Drug: Canrenone
7 Completed Cardiovascular Evaluation of Adult PHA 1 Patients
Condition: Pseudohypoaldosteronism Type 1
Intervention:
8 Completed The Role of Mineralocorticoid Receptors in Vascular Function
Condition: Apparent Mineralocorticoid Excess (AME)
Interventions: Drug: Glycyrrhetic Acid;   Drug: Placebo
9 Not yet recruiting Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
Condition: End Stage Renal Disease / Hemodialysis
Intervention: Drug: Spironolactone
10 Recruiting Aldosterone and the Metabolic Syndrome
Conditions: Metabolic Diseases;   Diabetes Mellitus;   Endocrine System Diseases;   Glucose Metabolism Disorders
Interventions: Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation;   Drug: Administration of Aliskiren, Spironolactone, or Placebo;   Drug: Increased Dose, Combination, or Placebo
11 Recruiting Eplerenone and Extracellular Adenosine Formation
Condition: Pharmacodynamics
Interventions: Drug: Eplerenone;   Drug: Placebo
12 Completed
Has Results 		Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Conditions: Systemic Arterial Hypertension;   Hypertension Resistant to Conventional Therapy;   Myocardial Infarction;   Stroke
Intervention: Drug: Anti-hypertensive drug treatment
13 Recruiting Fludrocortisone and Information Processing in Healthy Volunteers
Condition: Depression
Interventions: Drug: Fludrocortisone;   Drug: Placebo
14 Recruiting EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety
Conditions: Chronic Kidney Insufficiency;   Kidney Transplantation
Intervention: Drug: Eplerenone
15 Terminated Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
Condition: Chronic Kidney Disease
Intervention: Drug: Eplerenone
16 Not yet recruiting Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
Conditions: Primary Aldosteronism;   Primary Hyperaldosteronism
Intervention:
17 Recruiting Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Condition: Atrial Fibrillation
Interventions: Other: Upstream therapy;   Other: Conventional rhythm control
18 Completed Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Condition: End-stage Renal Failure
Intervention: Drug: Spironolactone
19 Completed Brain Receptor Function in Post-Traumatic Stress Disorder
Condition: Post-Traumatic Stress Disorder
Intervention: Drug: RU-486 (Mifepristone)
20 Completed Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
Conditions: Chronic Kidney Disease;   Proteinuria
Intervention: Drug: Spironolactone (Spironol) 25 mg
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years